© Drug Hunter Inc. 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > AZD4573
<< Back to December
short engagement, selective CDK9 kinase inh.
IV treatment in Ph. I for RR-heme cancers
shortened t1/2 from prior preclin. candidate
J. Med. Chem., Dec. 11, 2020
AstraZeneca, Cambridge, UK / Boston, MA
AstraZeneca selective CDK9 kinase inhibitor
Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.